ER+/ HER2-VE Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "ER+/ HER2-VE Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in ER+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the ER+/ HER2-VE Breast Cancer Pipeline Report
• DelveInsight's ER+/ HER2-VE Breast Cancer pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for ER+/ HER2-VE Breast Cancer treatment.
• The leading ER+/ HER2-VE Breast Cancer Companies working in the market include BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
• Promising ER+/ HER2-VE Breast Cancer Therapies in the various stages of development include ART6043, Olaparib, Talazoparib, and others
• February 2024:- Artios Pharma Ltd.- A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors. The study will consist of two parts: Part A (dose-escalation phase) & Part B (dose-expansion phase).

Request a sample and discover the recent advances in ER+/ HER2-VE Breast Cancer @ ER+/ HER2-VE Breast Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

ER+/ HER2-VE Breast Cancer Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70-80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen. HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don't have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.

ER+/ HER2-VE Breast Cancer Emerging Drugs Profile
• AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.

• BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.

Learn more about ER+/ HER2-VE Breast Cancer in clinical trials @ ER+/ HER2-VE Breast Cancer Drugs- https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

ER+/ HER2-VE Breast Cancer Therapeutics Assessment
There are approx. 40+ key companies which are developing the ER+/ HER2-VE Breast Cancer. The companies which have their ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.

DelveInsight's ER+/ HER2-VE Breast Cancer Pipeline Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Discover more about ER+/ HER2-VE Breast Cancer in development @ ER+/ HER2-VE Breast Cancer Clinical Trials- https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

ER+/ HER2-VE Breast Cancer Companies
BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.

ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

ER+/ HER2-VE Breast Cancer Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

To know more about ER+/ HER2-VE Breast Cancer, visit @ ER+/ HER2-VE Breast Cancer Segmentation- https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the ER+/ HER2-VE Breast Cancer Pipeline Report
• Coverage- Global
• ER+/ HER2-VE Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• ER+/ HER2-VE Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• ER+/ HER2-VE Breast Cancer Companies- BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
• ER+/ HER2-VE Breast Cancer Therapies- ART6043, Olaparib, Talazoparib, and others

For further information on the ER+/ HER2-VE Breast Cancer Pipeline Therapeutics, reach out @ ER+/ HER2-VE Breast Cancer Products Development- https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. ER+/ HER2-VE Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. AZD9833: Astrazeneca
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. BGB-290: BeiGene
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. OP-1250: Olema Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. ER+/ HER2-VE Breast Cancer Key Companies
20. ER+/ HER2-VE Breast Cancer Key Products
21. ER+/ HER2-VE Breast Cancer- Unmet Needs
22. ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
23. ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
24. ER+/ HER2-VE Breast Cancer Analyst Views
25. ER+/ HER2-VE Breast Cancer Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.